Caplin Point Lab
Ticker > Company >

Caplin Point Lab share price

Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT BSE: 524742 SECTOR: Pharmaceuticals & Drugs  217k   1k   250

1856.60
-43.50 (-2.29%)
BSE: 09 May 04:01 PM

Price Summary

Today's High

₹ 1881

Today's Low

₹ 1839.05

52 Week High

₹ 2636

52 Week Low

₹ 1221

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 14112.33 Cr.

Enterprise Value

₹ 13896.55 Cr.

No. of Shares

7.6 Cr.

P/E

43.71

P/B

8.77

Face Value

₹ 2

Div. Yield

0.27 %

Book Value (TTM)

₹  211.76

CASH

₹ 215.78 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

70.56 %

EPS (TTM)

₹  42.48

Sales Growth

18.25%

ROE

22.69 %

ROCE

28.92%

Profit Growth

21.11 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 21 Indices.

NFT500MOM50

Nifty500 Momentum 50
48948.7
  -356.650000000001 (-0.72334949452747%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
45290.75
  -149.050000000003 (-0.328016408522935%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
41288.55
  -394.5 (-0.946427864563648%)

NFT500MOQ50

Nifty500 Multicap Momentum Quality 50 index
38765.45
  6.54999999999563 (0.0168993444086274%)

NFT500MULTI

Nifty500 Multifactor MQVLv 50
29311.7
  -103.349999999999 (-0.351350754120761%)

NFTSMLCAP250Q50

Nifty Smallcap250 Quality 50
23936.8
  -168.799999999999 (-0.700252223549713%)

NIFTY500

Nifty 500
21675.55
  -167.5 (-0.766834301986219%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17953.75
  -38.4500000000007 (-0.213703716054736%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16256.3
  -87.6500000000015 (-0.536284068416759%)

NIFTYSMALLCAP250

Nifty Smallcap 250
15080.45
  -100 (-0.658742000401835%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14882.4
  -96.8000000000011 (-0.646229438154244%)

NFT500EQUAL

Nifty 500 Equal Weight
12786.55
  -50.1000000000004 (-0.390288743558487%)

NIFTYTOTALMCAP

Nifty Total Market index
12168.05
  -91.1000000000004 (-0.743118405435939%)

SMLCAP

S&P Bse Small Cap
46741.95
  -140.780000000006 (-0.30028114830345%)

BSE HC

S&P Bse Healthcare
41222.6
  -65.3400000000038 (-0.158254444275985%)

BSE500

S&P Bse 500
34105.3
  -234.399999999994 (-0.682591868886429%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
10904.46
  -18.8900000000012 (-0.17293229641091%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

BSE1000

Bse 1000
10119.33
  -66.2999999999993 (-0.650917027223641%)

SML250

S&P Bse 250 SmallCap
6059.13
  -33.1899999999996 (-0.544784252961095%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year18.25%
3 Year9%
5 Year3.09%

Profit Growth

1 Year21.11%
3 Year22%
5 Year13.87%

ROE%

1 Year22.69%
3 Year22.77%
5 Year26.13%

ROCE %

1 Year28.92%
3 Year28.96%
5 Year33.37%

Debt/Equity

0

Price to Cash Flow

127.13

Interest Cover Ratio

3658.4

CFO/PAT (5 Yr. Avg.)

0.831101666165743

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 70.56 0.00
Dec 2024 70.56 0.00
Sep 2024 70.56 0.00
Jun 2024 70.56 0.00
Mar 2024 70.62 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 22.002876510717% for the Past 3 years.
  • Company has been maintaining healthy ROE of 22.7698637935884% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.9639962673565% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 3658.4.
  • The Company has been maintaining an effective average operating margins of 42.3237648871538% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -29.1719 days.
  • Company has a healthy liquidity position with current ratio of 5.8935.
  • The company has a high promoter holding of 70.56%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 55.9001870103991.

 Limitations

  • The company has shown a poor revenue growth of 9.00022007207701% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 31.2911.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 132.83 139.38 185.64 207.93 185.23
Total Expenditure 69.51 81.7 104.26 109.77 107.84
Operating Profit 63.32 57.68 81.38 98.16 77.39
Other Income 17.9 36.18 21.5 43.01 28.83
Interest 0.03 0.02 0.02 0.02 0.04
Depreciation 6.76 6.93 6.18 6.49 6.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 74.43 86.91 96.68 134.66 100.17
Tax 18.98 17.03 24.14 28.92 25.46
Profit After Tax 55.45 69.88 72.54 105.74 74.71
Adjusted EPS (Rs) 7.3 9.2 9.54 13.91 9.83

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 527.83 482.68 528.06 528.61 625.09
Total Expenditure 320.83 273.14 308.58 309.23 338.01
Operating Profit 206.99 209.54 219.48 219.38 287.08
Other Income 65.97 23.01 56.69 99.54 105.84
Interest 0.19 0.17 0.09 0.12 0.1
Depreciation 19.65 22.44 25.77 25.65 27.08
Exceptional Items 0 0 0 0 0
Profit Before Tax 253.12 209.94 250.31 293.15 365.74
Tax 55.49 53.71 62.44 58.89 82.03
Net Profit 197.64 156.23 187.87 234.26 283.71
Adjusted EPS (Rs.) 26.13 20.65 24.79 30.86 37.35

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 15.13 15.13 15.16 15.18 15.19
Total Reserves 584.78 743.54 915.49 1124.73 1374.96
Borrowings 0.02 0 0 0 0
Other N/C liabilities 27.15 24.99 24.63 16.42 12.86
Current liabilities 64.26 77.33 98.88 146.85 119.3
Total Liabilities 691.33 860.99 1054.16 1303.18 1522.31
Assets
Net Block 166.93 182.68 162.46 156.85 165.79
Capital WIP 3.77 1.36 1.73 42.68 27.75
Intangible WIP 0 0 0.87 0 0
Investments 135.54 138.64 212.73 274.97 346.17
Loans & Advances 4.36 5.67 70.7 164.7 272.07
Other N/C Assets 0 20 0 2.28 7.43
Current Assets 380.74 512.64 605.67 661.7 703.1
Total Assets 691.33 860.99 1054.16 1303.18 1522.31
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 253.12 209.94 250.31 293.15 365.74
Adjustment -32.58 7.75 -19.43 -59.57 -68.57
Changes in Assets & Liabilities -83.19 131.85 62.07 -11.45 -99.07
Tax Paid -50.35 -54.9 -61.98 -65.03 -87.09
Operating Cash Flow 87.01 294.64 230.97 157.1 111.01
Investing Cash Flow -41 -3.9 -276.02 -85.67 -118.13
Financing Cash Flow -32.92 -3.47 -22.76 -30.42 -34.26
Net Cash Flow 13.09 287.27 -67.81 41.01 -41.38

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 70.62 70.56 70.56 70.56 70.56
ashok gorkey partheeban 11.92 11.91 11.91 11.91 11.91
first dimension holdings ... 0.49 0.49 0.49 0.49 0.49
kiraviz properties and co... 0.20 0.20 0.20 0.20 0.20
may india property privat... 2.79 2.79 2.79 2.79 2.79
p vijayalakshmi 24.73 24.71 24.71 24.71 24.71
paarthipan c c 18.66 18.64 18.64 18.64 18.64
partheeban vivek siddarth... 11.85 11.84 11.84 11.84 11.84
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 29.38 29.44 29.44 29.44 29.44
investor education and pr... 2.72 2.72 2.71 2.76 2.74
llp 0.49 0.52 0.50 0.49 0.49
uti small cap fund - 1.21 1.47 1.39 1.27
foreign portfolio inv1&2 - - - 0.02 -
suresh kumar agarwal 1.32 1.32 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Caplin Point Laboratories informs about financial results 7 May, 5:11 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Phytonadione Injectable Emulsion 23 Apr, 3:18 PM Caplin Point Laboratories informs about press release 23 Apr, 12:31 PM Caplin Point Laboratories’ arm acquires Neoethicals Chile SpA 2 Apr, 5:05 PM Caplin Point’s arm gets USFDA’s final nod for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution 27 Feb, 9:37 AM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Laboratories informs about press release 5 Feb, 2:50 PM Caplin Point’s arm gets USFDA’s approval for Procainamide Hydrochloride Injection 5 Feb, 12:20 PM Caplin Point’s arm gets USFDA’s approval for Levetiracetam in Sodium Chloride Injection, infusion bags 17 Jan, 2:28 PM Caplin Point Laboratories receives EIR from USFDA 7 Jan, 10:59 AM Caplin Point Laboratories informs about press release 16 Dec, 5:22 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Difluprednate Ophthalmic Emulsion 16 Dec, 12:48 PM Caplin Point Laboratories informs about loss of share certificate 12 Dec, 2:37 PM Caplin Point Laboratories informs about loss of share certificate 15 Nov, 4:54 PM Caplin Point Lab - Quaterly Results 7 Nov, 1:42 PM Caplin Point Lab - Quaterly Results 7 Nov, 1:42 PM Caplin Point Lab - Quaterly Results 7 Nov, 1:42 PM Caplin Point Laboratories informs about certificate 10 Oct, 4:26 PM ANVISA-Brazil concludes inspection at manufacturing facility of Caplin Point’s arm 17 Aug, 4:29 PM USFDA completes unannounced inspection at Caplin Point’s arm’s manufacturing facility in Tamil Nadu 10 Aug, 10:26 AM Caplin Point Laboratories informs about press release 8 Aug, 1:11 PM Caplin Point Laboratories’ arm gets USFDA’s final nod for Timolol Maleate Ophthalmic Solution 8 Aug, 1:07 PM Caplin Point Lab - Quaterly Results 7 Aug, 1:05 PM Caplin Point Lab - Quaterly Results 7 Aug, 1:05 PM Caplin Point Lab - Quaterly Results 7 Aug, 1:05 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Ephedrine Sulfate Injection 19 Jul, 11:28 AM Caplin Point Laboratories informs about loss of share certificate 24 Jun, 12:17 PM Caplin Point Laboratories informs about press release 24 May, 1:03 PM Caplin Point’s arm gets USFDA’s approval for Phenylephrine Hydrochloride Ophthalmic Solution 24 May, 11:27 AM Caplin Point Lab - Quaterly Results 16 May, 1:55 PM Caplin Point Lab - Quaterly Results 16 May, 1:55 PM Caplin Point Lab - Quaterly Results 16 May, 1:55 PM Caplin Point gets Colombia's INVIMA approval for Softgel Capsules division 6 May, 11:40 AM Caplin Point Laboratories informs about press release 16 Apr, 2:49 PM Caplin Point Laboratories’ arm gets final approval from USFDA for Ofloxacin Ophthalmic Solution 16 Apr, 12:30 PM Caplin Point Laboratories informs about press release 28 Mar, 12:37 PM Caplin Point Laboratories’ arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution 28 Mar, 11:12 AM Caplin Point Laboratories informs about press release 27 Mar, 2:58 PM Caplin Point Laboratories’ arm completes new Oncology facility in Kakkalur 27 Mar, 11:30 AM Caplin Point Laboratories informs about loss of share certificate 27 Feb, 2:31 PM Caplin Point Laboratories informs about details of loss of certificate 19 Feb, 2:48 PM Caplin Point Lab - Quaterly Results 9 Feb, 12:46 PM Caplin Point Lab - Quaterly Results 9 Feb, 12:46 PM Caplin Point Lab - Quaterly Results 9 Feb, 12:46 PM Caplin Point along with arms to invest Rs 700 crore in Tamil Nadu 9 Jan, 11:11 AM Caplin Point Laboratories’ arm gets USFDA’s final approval for Ofloxacin Otic Solution 8 Jan, 12:41 PM Caplin Point Laboratories informs about earnings call transcript 18 Nov, 2:51 PM Caplin Point Lab - Quaterly Results 9 Nov, 12:43 PM

Caplin Point Lab Stock Price Analysis and Quick Research Report. Is Caplin Point Lab an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Caplin Point Lab and its performance over the period of time. Caplin Point Lab stock price today is Rs 1860.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Caplin Point Lab cash from the operating activity was Rs 111.01 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Caplin Point Lab has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Caplin Point Lab , the EPS growth was 21.0292 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Caplin Point Lab has OPM of 45.9261866291254 % which is a good sign for profitability.
     
  • ROE: Caplin Point Lab have a healthy ROE of 22.6925 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Caplin Point Lab is Rs 1860.9. One can use valuation calculators of ticker to know if Caplin Point Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Caplin Point Lab

Caplin Point Laboratories Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Welcome to our website and our comprehensive analysis of Caplin Point Laboratories Ltd. for long-term stock investors looking for detailed insights and information about the company's performance and potential. On our website, we provide a wide range of tools and features to empower investors, including pre-built screening tools and premium analysis tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Caplin Point Laboratories Ltd.Share Price Analysis:

Analyzing the historical share prices of Caplin Point Laboratories Ltd. is vital for long-term investors striving to understand the stock's performance over time. By monitoring share prices, investors can identify trends and patterns that may influence their investment decisions. On the ticker website, we provide an accurate and up-to-date analysis of Caplin Point Laboratories Ltd.'s share prices, accompanied by interactive price charts, to assist investors in monitoring the stock's performance and identifying potential entry and exit points. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Caplin Point Laboratories Ltd.Balance Sheet:

Analyzing the balance sheet of Caplin Point Laboratories Ltd. is essential in gauging the company's financial health and stability, evaluating the quality of earnings, and assessing the sustainability of growth for long-term investors. On the ticker website, we provide Caplin Point Laboratories Ltd.'s balance sheet for thorough analysis, enabling investors to make well-informed investment decisions based on the company's financial position.

Caplin Point Laboratories Ltd.Annual Report:

Caplin Point Laboratories Ltd.'s annual report provides detailed insights into the company's performance, strategies, and future outlook. This report includes information about the company's business operations, financials, and corporate governance practices. For long-term investors, reviewing the annual report is highly recommended as it offers valuable insights into the company's growth prospects and helps assess its potential for generating sustainable returns. On ticker website, investors can conveniently access and download the annual reports of Caplin Point Laboratories Ltd. for in-depth analysis.

Caplin Point Laboratories Ltd.Dividend Analysis:

Caplin Point Laboratories Ltd. has consistently rewarded its investors through dividends, making tracking its dividend payments and announcements crucial in understanding the company's financial performance. By analyzing historical dividend payments and announcements of Caplin Point Laboratories Ltd. on our website, investors can monitor the company's dividend-paying track record using our user-friendly interface.

Caplin Point Laboratories Ltd.Quarterly Result Evaluation:

Keeping track of the quarterly results of Caplin Point Laboratories Ltd. is paramount for long-term investors. Quarterly reports offer insights into the company's revenue, earnings, and relevant financial metrics. On our website, investors can easily download quarterly reports of Caplin Point Laboratories Ltd. for thorough analysis. By studying these reports, investors can gain a comprehensive understanding of the company's financial performance over time, enabling better decision-making when it comes to long-term investments.

Caplin Point Laboratories Ltd.Stock Price Analysis:

Analyzing the price movement of Caplin Point Laboratories Ltd.'s stock is a critical tool for long-term investors. Our website provides detailed price charts that assist investors in identifying trends and patterns in the stock's performance. By studying the historical price movements, investors can identify potential entry and exit points. Paired with our pre-built screening tools, investors can make well-informed decisions based on thorough analysis of Caplin Point Laboratories Ltd.'s stock price. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Caplin Point Laboratories Ltd.Price Chart Analysis:

On our website, investors can access interactive price charts that visually represent the historical movement of Caplin Point Laboratories Ltd.'s stock price. These charts enable investors to identify patterns, trends, and potential opportunities based on the stock's performance. By analyzing the price chart, investors can enhance their understanding of the stock's behavior, and couple it with our pre-built screening tools to make informed investment decisions.

Caplin Point Laboratories Ltd.News Coverage

Staying updated on the latest news and developments related to Caplin Point Laboratories Ltd. is crucial for investors. Our website provides regular news updates related to the company, including company announcements, industry trends, and macroeconomic factors that may impact the stock price. By staying informed, investors can make well-informed decisions based on the most current and relevant information available.

Caplin Point Laboratories Ltd.Conference Call Transcripts:

Conference call transcripts provide in-depth insights into the company's management discussions and interactions with analysts during important conference calls. On our website, investors can conveniently download the transcripts of Caplin Point Laboratories Ltd.'s conference calls, providing valuable knowledge about the company's strategic direction, future plans, and management outlook. By studying these transcripts, investors can gain a comprehensive understanding of Caplin Point Laboratories Ltd.'s performance and prospects.

Caplin Point Laboratories Ltd.Investor Presentations:

Caplin Point Laboratories Ltd. conducts investor presentations to provide an overview of its operations, financial performance, and growth prospects. These presentations offer insights into the company's strategies and initiatives, providing a clearer understanding of the company's goals and direction. On our website, investors can access Caplin Point Laboratories Ltd.'s investors presentations, ensuring they stay informed about the company's initiatives, understand its long-term vision, and assess its potential for generating sustainable returns. These presentations can be complemented and analyzed using our premium analysis tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Caplin Point Laboratories Ltd.Promoters

The promoters of Caplin Point Laboratories Ltd. play a critical role in the company's management and decision-making processes. As an investor, understanding the background and track record of the promoters is essential in gauging their contributions to the company's success. On the ticker website, investors can find valuable information about the promoters of Caplin Point Laboratories Ltd., enabling them to assess their contributions to the company and make well-informed decisions based on comprehensive analysis.

Caplin Point Laboratories Ltd.Shareholders

Understanding the major shareholders of Caplin Point Laboratories Ltd. is critical in assessing the company's ownership structure and potential influences on decision-making. Ticker website provides a detailed breakdown of major shareholders, including institutional and retail ownership. This information helps investors gauge the level of ownership concentration in the stock and evaluate potential risks and opportunities associated with the company's ownership dynamics.

Caplin Point Laboratories Limited ROCE

Caplin Point Laboratories Limited's ROCE (Return on Capital Employed) is a financial metric that measures how efficiently a company is using its capital to generate profits. This ratio is an essential indicator of a company's profitability, as it measures how much profit a company is making from the capital it has invested. You can find Caplin Point Laboratories Limited's ROCE data in the financials table or ratio section.

Caplin Point Laboratories Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a financial ratio that evaluates a company's operating performance. It measures the company's earnings before accounting for the effects of interest, taxes, depreciation, and amortization. Caplin Point Laboratories Limited's EBITDA can be found in the financials table or ratio section.

Caplin Point Laboratories Limited DPS

DPS (Dividend Per Share) is a financial metric that shows how much a company is paying its shareholders per share. Dividends are distributed to the shareholders as a portion of a company's profits. Caplin Point Laboratories Limited's DPS can be found in the financials table or ratio section.

Caplin Point Laboratories Limited EPS

EPS (Earnings Per Share) is a financial metric that measures the amount of earnings per share of a company's common stock. It is calculated by dividing a company's net earnings by the total number of shares outstanding. Caplin Point Laboratories Limited's EPS can be found in the financials table or ratio section.

In conclusion, Caplin Point Laboratories Limited's stock analysis page provides key financial metrics necessary for analyzing a company's performance in the stock market. These metrics can help investors make informed decisions about investing in the company. 

Caplin Point Laboratories Balance Sheet Evolution

Caplin Point Laboratories' Share Capital Stability

Caplin Point Laboratories has maintained a stable share capital from March 2020 (Rs 15.13 Cr) with a slight increase by March 2024 to Rs 15.19 Cr. This consistency reflects the company's stable financing strategy and shareholder confidence.

Rise in Reserves at Caplin Point Laboratories

There is a notable increase in the total reserves of Caplin Point Laboratories, ascending from Rs 584.78 Cr in March 2020 to Rs 1,374.96 Cr in March 2024. The robust growth in reserves underscores the company's profitability and financial health.

Caplin Point Laboratories' Minimal Borrowings

Caplin Point Laboratories exhibited nearly zero borrowings from March 2021 onwards, showcasing the company's strong liquidity position and its ability to fund operations without leveraging.

Caplin Point Laboratories' Asset Growth

The asset growth journey of Caplin Point Laboratories showcases a total asset increase from Rs 691.33 Cr in March 2020 to Rs 1,522.31 Cr by March 2024. This growth signifies an enhancement in operational capabilities and asset acquisition for future ventures.

This data represents an analysis of the standalone balance sheet of Caplin Point Laboratories and provides insights into its financial stature over the years. Analysis like this can benefit investors exploring opportunities in the healthcare sector across various market environments, including the NSE BSE indices.

Read More
X